Business Wire

VALBIOTIS Opens up Its Capital to a New Shareholder, AMIRAL GESTION, at a Share Price of 4.50 EUROS, Representing a Premium of 5.4% Compared to the Closing Stock Exchange Price on July 16, 2020


Regulatory News:

VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL, French PEA/SME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces a capital increase via a €2 M private placement by AMIRAL GESTION, through its NOVA2 and Sextant PME funds, within an offer for the benefit of qualified investors referred to in Article L.411-2 1° of the French Monetary and Financial Code.

The subscription price for the VALBIOTIS shares was set at €4.50 per share (issuance fee included), which represents a premium of 5.4% compared to the closing price on 16 July 2020. This capital increase enables VALBIOTIS to benefit from additional financial resources for its development, notably its three research programs against hypercholesterolemia, arterial hypertension and hepatic steatosis.

Sébastien PELTIER, Chairman of the VALBIOTIS Board of Directors stated:
“We would like to thank our new shareholder, AMIRAL GESTION, for its trust and support. The funds raised considerably bolster our financial position and confirm investors interest in our development model, which has led to sign a partnership with Nestlé Health Science for the reduction of Type 2 diabetes risk factors. After this first success, this fundraising demonstrates our desire to further expand the room our Company has to manoeuvre as we pursue our development plan, addressing huge markets such as hypercholesterolemia, arterial hypertension and hepatic steatosis.”

The private placement modalities

The capital increase was made with the removal of the preferential subscription right from qualified investors, in the context of an offer within the meaning of Article L.411-2 1° of the French Monetary and Financial Code of new shares (the "Offer"), in accordance with the 12th resolution passed by the Company’s Combined General Meeting on May 28, 2020.

An overall number of 444,444 New Shares (the “New Shares”), with a unit face value of €0.10, were issued to AMIRAL GESTION, through its NOVA2 and Sextant PME funds, representing 6.15% of the share capital of the Company before the Offer was made and 5.79% of the share capital of the Company after the achievement of the Offer.

The issuing price of the New Shares was set at €4.50, that represents a premium of 5.4% compared to the closing price of the Company’s share on the Euronext Growth Paris on July 16, 2020, i.e. €4.27.

The settlement and delivery of the New Shares and their admission to trading on the Euronext Growth Paris market is scheduled for July 21, 2020. The New Shares will be subject to all the statutory provisions and will be assimilated to the old shares as soon as the Capital Increase is finally realised, they will carry current use and will be admitted to trading on the Euronext Growth Paris market on the same listing line as the shares of the Company already listed under the same ISIN code FR0013254851 – ALVAL.

Capital breakdown

The Company’s share capital will be composed of 7,671,144 shares upon completion of the operation.

For information, the interest of a shareholder with 1% of the Company’s share capital prior to the issuing will be brought to 0.94%.

Therefore, after the capital increase, the Company’s share capital will be broken down as follows:


Number of shares

% capital

Voting rights

% capital

Members of the Board of Directors





Djanka Investissement
(company under the control of Sébastien PELTIER)





Financière Eloujon
(company under the control of Jocelyn PINEAU)










Financial investors





Amiral Gestion










Members of the supervisory board










Liquidity contract










Within the framework of the Private Placement, the Company concluded a lock-up agreement for a duration of 90 days starting from the date of settlement of this operation.

Portzamparc (Groupe BNP Paribas) acted as Lead Arranger and Bookrunner of the operation.

As per the provisions of Article 211-3 of the General Regulations of the Financial Market Authority, the offer of Company shares within the framework of this Private Placement did not give rise to a prospectus submitted for the approval of the Financial Market Authority. Detailed information concerning VALBIOTIS, in particular regarding its activity, results and corresponding risk factors, appears in the annual financial report for the business year ending on 31 December 2019, which can be consulted on its website (, along with further regulatory information and all of the Company’s press releases.

VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.

VALBIOTIS has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of nutritional health solutions designed to reduce the risk of major metabolic diseases, based on a multi-target approach and made possible by the use of plant-based ingredients.

Its products are intended to be licensed to players in the health world.

VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63).

VALBIOTIS is a member of the "BPI Excellence" network and received the "Innovative Company" status accorded by BPI France. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs by obtaining support from the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company.

Find out more about VALBIOTIS:

Name: Valbiotis
ISIN code: FR0013254851
Mnemonic code: ALVAL

Certain statements contained in this press release constitute forward-looking statements. Although the Company considers the projections made on the basis of the forward-looking statements to be reasonable, they are based on many risks and uncertainties, which could lead to actual results different from those contained in the forward-looking statements.

This press release is for informational purposes only, and the information contained therein does not constitute an offer to sell or the solicitation of an offer to buy securities of the Company in any jurisdiction, including in France.

The distribution of this press release may be restricted by certain local laws. The beneficiaries of this press release are required to inform themselves of the possible restrictions to which they may be constrained, and if necessary to observe them. This press release does not constitute an offer or a solicitation of an offer to buy or subscribe for securities in France.

This press release is a promotional communication and does not constitute a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017 (the "Prospectus Regulation").

In France, the offer of the shares of the Company described above will be made exclusively within the framework of an offer for the benefit of qualified investors within the meaning of article 2 (1) (e) of the Prospectus Regulation, in accordance with Article L. 411-2 of the Monetary and Financial Code and the applicable regulatory provisions. No prospectus has been nor will be published or approved by the Autorité des Marchés Financiers.

With regard to the Member States of the European Economic Area other than France (the "Member States"), no action has been taken or will be taken to allow a public offering of securities making it necessary to publication of a prospectus in one of these Member States. Consequently, the securities cannot be offered and will not be offered in any of the Member States (other than France), except in accordance with the exemptions provided for in Article 1 (4) of the Prospectus Regulation, or in other cases not requiring not the publication by VALBIOTIS of a prospectus under article 3 of the Prospectus Regulation and / or of the regulations applicable in these Member States.

As regards the United Kingdom, the press release is only intended for persons who are (i) "investment professionals" (persons with professional experience in investment matters) within the meaning of Article 19 (5 ) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"), (ii) being persons within the scope of section 49 (2) (a) to (d) (“high net worth companies, unincorporated associations, etc.”) of the Order, or (iii) persons to whom an invitation or an invitation to participate in an investment activity (within the meaning of article 21 of the Financial Services and Markets Act 2000) in the context of the issue or sale of financial securities could be legally addressed (all of these persons being designated together as the "Relevant Persons").

This press release is addressed only to Relevant Persons and no person other than a Relevant Person may use or rely on this press release for any action. Any investment or investment activity to which this press release refers is only accessible to Relevant Persons and must only be carried out with Relevant Persons.

This press release is not intended for publication or distribution, direct or indirect, in the United States and does not constitute or form part of any offer of securities in the United States or any solicitation to purchase, subscription or sale of securities in the United States. The new shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"). The Securities will not be and may not be sold or offered to the public in the United States without registration or an exemption from registration under the Securities Act. VALBIOTIS does not intend to register or conduct a public offering of securities in the United States.

This press release is not intended for publication or distribution in the United States, Canada, Japan or Australia. The information contained in this press release does not constitute an offer of securities in the United States, Canada, Japan or Australia or any other jurisdiction in which such an offer would be considered illegal.

Contact information

+33 5 46 28 62 58

Stéphane RUIZ
+33 1 56 88 11 14

+33 6 85 91 32 56

About Business Wire

Business Wire
Business Wire

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lenovo Delivers Outstanding Q1 Performance and Strong Growth, Overcoming Challenging Global Environment13.8.2020 06:46:00 CESTPress release

Lenovo Group (HKSE: 992) PINK SHEETS: LNVGY) today announced Group revenue in the first quarter of US$13.3 billion, up almost 7% year-on-year (up 10% year-on-year excluding currency impact). Pre-tax income grew 38% compared to the same quarter a year earlier, to US$332 million, while net income also increased by 31% year-on-year to US$213 million. Basic earnings per share for the first quarter were 1.80 US cents or 13.95 HK cents. “Our outstanding performance last quarter proves that Lenovo has quickly regained momentum from the impact of the pandemic and is capturing the new opportunities emerging from remote working, education and accelerated digitalization,” said Yang Yuanqing, Lenovo Chairman and CEO. “While the world continues to face challenges, Lenovo is focused on delivering sustainable growth through our core businesses as well as the new services and solutions opportunities presented by our service-led intelligent transformation.” Global economic factors The last quarter has

Win a Tablet with WorldRemit’s Back to School Competition!13.8.2020 03:11:00 CESTPress release

WorldRemit, a leading international payments company, is giving away 150 tablet computers to students in the Philippines! Public schools in the Philippines are scheduled to reopen from 24th August, depending on compliance with the local COVID-19 Risk Severity Classification. WorldRemit, which has a large presence in the Philippines, wants to create opportunities by widening access to education with this generous offer. Customers will have the chance to win a tablet computer by simply making a transfer to the Philippines using the WorldRemit app or website between 1st July and 30th September 2020 and ensuring that they have registered for the offer online at: Every Friday of each week from 14th August 2020 until 2nd October 2020, WorldRemit will randomly select between 16 and 20 winners. A tablet computer will then be sent to the winners’ chosen recipient who can demonstrate they are currently a student in the Philippines. “As a compa

Lattice Sentry Solutions Stack and SupplyGuard Service Deliver End-to-End Supply Chain Protection with Dynamic Trust12.8.2020 22:00:00 CESTPress release

Lattice Semiconductor Corporation (NASDAQ: LSCC), the low power programmable leader, today launched the Lattice Sentry™ solutions stack and the Lattice SupplyGuard™ supply chain protection service. The Sentry stack is a robust combination of customizable embedded software, reference designs, IP, and development tools to accelerate the implementation of secure systems compliant with NIST Platform Firmware Resiliency (PFR) Guidelines (NIST SP-800-193). The Lattice SupplyGuard service extends the system protection provided by the Sentry stack throughout today’s challenging and rapidly changing supply chain by delivering factory-locked devices to protect them from attacks like cloning and malware insertion, and enables secure device ownership transfer. These hardware security solutions are increasingly important to a range of applications, including communications, datacenter, industrial, automotive, aerospace, and client computing. This press release features multimedia. View the full rel

Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease12.8.2020 14:36:00 CESTPress release

Boehringer Ingelheim today announced that the first patient has enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents between six and 17 years old with clinically significant fibrosing interstitial lung disease (ILD). Childhood ILD (chILD) includes more than 200 rare respiratory disorders that can affect infants, children and adolescents, making it difficult for them to breathe. In some cases, fibrosis which involves scarring and damage to the lungs can develop. This can lead to a significant impact on the daily life of those affected, as well as their families, including high morbidity and mortality. There are currently no approved therapies available for the treatment of chILD. “Some children with interstitial lung disease may develop serious fibrosis that progresses,” said the coordinating investigator Prof. Robin Deterding, M.D., Director of the Breathing Institute, Children's Hospital Colorado. “Though the

Velodyne Lidar Powering Intelligent Traffic Management in Nevada12.8.2020 14:00:00 CESTPress release

Velodyne Lidar, Inc. today announced a partnership with University of Nevada, Reno to advance research in transportation infrastructure. The university’s Nevada Center for Applied Research purchased and, in conjunction with the Nevada DOT and Nevada Governor’s Office of Economic Development, is using Velodyne’s lidar sensors in its Intelligent Mobility initiative to collect data aimed at making transportation more efficient, sustainable and safe. This press release features multimedia. View the full release here: The University of Nevada, Reno’s Nevada Center for Applied Research has integrated Velodyne Ultra Puck lidar sensors with traffic signals to detect, count and track pedestrians, cyclists and traffic. (Photo: Velodyne Lidar, Inc.) The program has integrated Velodyne Ultra Puck lidar sensors with traffic signals to detect, count and track pedestrians, cyclists and traffic to help improve traffic analytics, congestion mana

Moody’s Analytics Three-Peats in Two Categories at Risk Technology Awards12.8.2020 13:30:00 CESTPress release

For the third straight year, Moody’s Analytics has won the Risk Technology Awards for Credit Data Provider of the Year and Wholesale Credit Modelling Software of the Year. These are two of our seven 2020 Risk Technology Awards spanning finance, accounting, regulatory, and credit functions. This press release features multimedia. View the full release here: “Our clients rely on Moody’s Analytics for a fast and comprehensive view of their credit risk exposure,” said Nihil Patel, Managing Director at Moody’s Analytics. “The pandemic has accelerated their need to consider multiple forward-looking signals to assess credit risk. We continue to invest—in more asset class coverage, in alternative data sources, in machine learning that produces new analytics and insights—to ensure that our clients have all the information they need to address their most pressing business needs.” Extensive credit data and modeling capabilities feature in

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom